H. Lundbeck A/S
HLUN-A
Classement en actions
#3070
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Prix de l'action
$7.07
Capitalisation boursière
$5.91B
Changement (1 jour)
-4.56%
Changement (1 an)
28.57%
Pays
DK
Échange H. Lundbeck A/S (HLUN-A)
Catégorie
Healthcare
Nombre d'actions en circulation pour H. Lundbeck A/S (HLUN-A)
Nombre d'actions en circulation au June 2026: 992.15M
Selon les derniers rapports financiers et le cours de l'action de H. Lundbeck A/S, le nombre actuel d'actions en circulation est de 992.15M. À la fin de December 2024, l'entreprise avait 991.44M actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de H. Lundbeck A/S (HLUN-A) de 2004 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2026 (TTM) | 992.15M | 0.00% |
| 2025 | 992.15M | 0.07% |
| 2024 | 991.44M | -0.08% |
| 2023 | 992.24M | -0.06% |
| 2022 | 992.87M | 24.94% |
| 2021 | 794.64M | 299.92% |
| 2020 | 198.70M | 0.01% |
| 2019 | 198.69M | 0.01% |
| 2018 | 198.68M | 0.59% |
| 2017 | 197.51M | 0.17% |
| 2016 | 197.19M | 0.36% |
| 2015 | 196.47M | 0.11% |
| 2014 | 196.25M | 0.06% |
| 2013 | 196.14M | 0.00% |
| 2012 | 196.13M | 0.01% |
| 2011 | 196.10M | -0.01% |
| 2010 | 196.12M | 0.00% |
| 2009 | 196.12M | -0.37% |
| 2008 | 196.84M | -3.97% |
| 2007 | 204.99M | -2.89% |
| 2006 | 211.10M | -6.00% |
| 2005 | 224.56M | -2.20% |
| 2004 | 229.61M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| 445.06M | -55.14% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| 105.38M | -89.38% |
US
|
|
| - | - |
IT
|
